HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides

Morgan G Mathieu, Ashley J Knights, Graham Pawelec, Catherine L Riley, Dorothee Wernet, François A Lemonnier, Per Thor Straten, Ludmila Mueller, Robert C Rees, Stephanie E B McArdle

24 Citationer (Scopus)

Abstract

There remains a need to identify novel epitopes of potential tumour target antigens for use in immunotherapy of cancer. Here, several melanoma tissues and cell lines but not normal tissues were found to overexpress the cancer-testis antigen HAGE at the mRNA and protein level. We identified a HAGE-derived 15-mer peptide containing a shorter predicted MHC class I-binding sequence within a class II-binding sequence. However, only the longer peptide was found to be both endogenously processed and immunogenic for T cells in transgenic mice in vivo, as well as for human T cells in vitro. A different class I-binding peptide, not contained within a longer class II sequence, was subsequently found to be both immunogenic and endogenously processed in transgenic mice, as was a second class II epitope. These novel HAGE-derived epitopes may contribute to the range of immunotherapeutic targets for use in cancer vaccination programs.

OriginalsprogEngelsk
TidsskriftCancer Immunology and Immunotherapy
Vol/bind56
Udgave nummer12
Sider (fra-til)1885-95
Antal sider11
ISSN0340-7004
DOI
StatusUdgivet - dec. 2007

Fingeraftryk

Dyk ned i forskningsemnerne om 'HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides'. Sammen danner de et unikt fingeraftryk.

Citationsformater